Discovery of oxindole‐based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation
作者:Onur Bender、Mai E. Shoman、Taha F. S. Ali、Rumeysa Dogan、Ismail Celik、Adriano Mollica、Mohammed I. A. Hamed、Omar M. Aly、Abdulwahab Alamri、Jowaher Alanazi、Nafees Ahemad、Siew Hua Gan、Jonaid Ahmad Malik、Sirajudheen Anwar、Arzu Atalay、Eman A. M. Beshr
DOI:10.1002/ardp.202200407
日期:2023.2
approximately 30% of acute myeloid leukemia (AML) patients. In the current study, the oxindole chemotype is employed as a structural motif for the design of new FLT3 inhibitors as potential hits for AML irradiation. Cell-based screening was performed with 18 oxindole derivatives and 5a–c inhibited 68%–73% and 83%–91% of internal tandem duplication (ITD)-mutated MV4-11 cell growth for 48- and 72-h treatments while